Business
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of $3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to host conference call and webcast today, May 14, ...
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively","length":99,"tagName":"p"},{"type":"text","content":"Adjusted EBITDA1 of $3.9 million","length":32,"tagName":"p"},{"type":"text","content":"Total net revenue of $18.5 million up 32% year-over-year","length":56,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time","length":90,"tagName":"p"},{"type":"text","content":"DENVER, CO / ACCESS Newswire / May 14, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 third quarter.","length":284,"tagName":"p"},{"type":"text","content":"Q3 2025 Highlights","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenue increased 32% to $18.5 million versus $14.0 million in Q3 fiscal 2024.","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 25% to $15.4 million versus $12.3 million in Q3 fiscal 2024.","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue increased 77% to $3.1 million versus $1.7 million in Q3 fiscal 2024.","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively, compared to a net loss of $2.9 million, or $0.52 net loss per share basic and diluted in Q3 fiscal 2024.","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA was $3.9 million compared to $0.9 million in Q3 fiscal 2024.","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents were $18.2 million at March 31, 2025.","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":709,"olType":false},{"type":"text","content":"Management Discussion","length":21,"tagName":"p"},{"type":"text","content":""I am extremely pleased with the operating and financial performance Aytu achieved during the 2025 third fiscal quarter, resulting in strong revenue growth of 32% led by improvement in bo...